Review



prostate carcinoma 3 cell line pc 3 castration resistant  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC prostate carcinoma 3 cell line pc 3 castration resistant
    Prostate Carcinoma 3 Cell Line Pc 3 Castration Resistant, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 15741 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/prostate carcinoma 3 cell line pc 3 castration resistant/product/ATCC
    Average 99 stars, based on 15741 article reviews
    prostate carcinoma 3 cell line pc 3 castration resistant - by Bioz Stars, 2026-02
    99/100 stars

    Images



    Similar Products

    prostate carcinoma 3 cell line pc 3 castration resistant  (ATCC)
    99
    ATCC prostate carcinoma 3 cell line pc 3 castration resistant
    Prostate Carcinoma 3 Cell Line Pc 3 Castration Resistant, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/prostate carcinoma 3 cell line pc 3 castration resistant/product/ATCC
    Average 99 stars, based on 1 article reviews
    prostate carcinoma 3 cell line pc 3 castration resistant - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier
    human prostate carcinoma  (ATCC)
    99
    ATCC human prostate carcinoma
    Human Prostate Carcinoma, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human prostate carcinoma/product/ATCC
    Average 99 stars, based on 1 article reviews
    human prostate carcinoma - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier
    androgen independent prostate carcinoma du 145 cell line  (ATCC)
    99
    ATCC androgen independent prostate carcinoma du 145 cell line
    Characterisation of prostate cancer-derived extracellular vesicles. EVs post differential ultracentrifugation were characterised using nanoparticle tracking analysis (NTA), immunoblotting analysis, and scanning electron microscopy (SEM). a ). Particle concentration and size of which three replicates of each sample were analysed by NTA independently. Data analysed by one-way ANOVA test and presented as mean bars (n = 3) ± SEM, the significant p-value is reported; * indicates p < 0.05, ** indicates p < 0.01. n.s. = not significant. b ) Representative graphs of prostate cancer EVs distribution from NTA software. c )Immunoblotting analysis of EVs from PC-3, LNCaP and <t>DU</t> <t>145</t> cells and cell lysates. Detection of EVs associated positive markers, syntenin, CD63, and negative marker calnexin. SEM images of d ) PC-3 EVs, e ) LNCaP EVs and f) DU 145 EVs with a range of 90 nm to 130 nm (magnification 62000x).
    Androgen Independent Prostate Carcinoma Du 145 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/androgen independent prostate carcinoma du 145 cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    androgen independent prostate carcinoma du 145 cell line - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier
    androgen independent prostate carcinoma du 145 cell line 249  (ATCC)
    99
    ATCC androgen independent prostate carcinoma du 145 cell line 249
    Characterisation of prostate cancer-derived extracellular vesicles. EVs post differential ultracentrifugation were characterised using nanoparticle tracking analysis (NTA), immunoblotting analysis, and scanning electron microscopy (SEM). a ). Particle concentration and size of which three replicates of each sample were analysed by NTA independently. Data analysed by one-way ANOVA test and presented as mean bars (n = 3) ± SEM, the significant p-value is reported; * indicates p < 0.05, ** indicates p < 0.01. n.s. = not significant. b ) Representative graphs of prostate cancer EVs distribution from NTA software. c )Immunoblotting analysis of EVs from PC-3, LNCaP and <t>DU</t> <t>145</t> cells and cell lysates. Detection of EVs associated positive markers, syntenin, CD63, and negative marker calnexin. SEM images of d ) PC-3 EVs, e ) LNCaP EVs and f) DU 145 EVs with a range of 90 nm to 130 nm (magnification 62000x).
    Androgen Independent Prostate Carcinoma Du 145 Cell Line 249, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/androgen independent prostate carcinoma du 145 cell line 249/product/ATCC
    Average 99 stars, based on 1 article reviews
    androgen independent prostate carcinoma du 145 cell line 249 - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier
    lncap metastatic prostate carcinoma cell line  (ATCC)
    99
    ATCC lncap metastatic prostate carcinoma cell line
    Characterisation of prostate cancer-derived extracellular vesicles. EVs post differential ultracentrifugation were characterised using nanoparticle tracking analysis (NTA), immunoblotting analysis, and scanning electron microscopy (SEM). a ). Particle concentration and size of which three replicates of each sample were analysed by NTA independently. Data analysed by one-way ANOVA test and presented as mean bars (n = 3) ± SEM, the significant p-value is reported; * indicates p < 0.05, ** indicates p < 0.01. n.s. = not significant. b ) Representative graphs of prostate cancer EVs distribution from NTA software. c )Immunoblotting analysis of EVs from PC-3, LNCaP and <t>DU</t> <t>145</t> cells and cell lysates. Detection of EVs associated positive markers, syntenin, CD63, and negative marker calnexin. SEM images of d ) PC-3 EVs, e ) LNCaP EVs and f) DU 145 EVs with a range of 90 nm to 130 nm (magnification 62000x).
    Lncap Metastatic Prostate Carcinoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lncap metastatic prostate carcinoma cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    lncap metastatic prostate carcinoma cell line - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier
    human prostate carcinoma epithelial cells 22rv1 cx0041 cell line  (Boster Bio)
    94
    Boster Bio human prostate carcinoma epithelial cells 22rv1 cx0041 cell line
    Characterisation of prostate cancer-derived extracellular vesicles. EVs post differential ultracentrifugation were characterised using nanoparticle tracking analysis (NTA), immunoblotting analysis, and scanning electron microscopy (SEM). a ). Particle concentration and size of which three replicates of each sample were analysed by NTA independently. Data analysed by one-way ANOVA test and presented as mean bars (n = 3) ± SEM, the significant p-value is reported; * indicates p < 0.05, ** indicates p < 0.01. n.s. = not significant. b ) Representative graphs of prostate cancer EVs distribution from NTA software. c )Immunoblotting analysis of EVs from PC-3, LNCaP and <t>DU</t> <t>145</t> cells and cell lysates. Detection of EVs associated positive markers, syntenin, CD63, and negative marker calnexin. SEM images of d ) PC-3 EVs, e ) LNCaP EVs and f) DU 145 EVs with a range of 90 nm to 130 nm (magnification 62000x).
    Human Prostate Carcinoma Epithelial Cells 22rv1 Cx0041 Cell Line, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human prostate carcinoma epithelial cells 22rv1 cx0041 cell line/product/Boster Bio
    Average 94 stars, based on 1 article reviews
    human prostate carcinoma epithelial cells 22rv1 cx0041 cell line - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    androgen independent prostate carcinoma pc 3 cell line  (ATCC)
    99
    ATCC androgen independent prostate carcinoma pc 3 cell line
    Characterisation of prostate cancer-derived extracellular vesicles. EVs post differential ultracentrifugation were characterised using nanoparticle tracking analysis (NTA), immunoblotting analysis, and scanning electron microscopy (SEM). a ). Particle concentration and size of which three replicates of each sample were analysed by NTA independently. Data analysed by one-way ANOVA test and presented as mean bars (n = 3) ± SEM, the significant p-value is reported; * indicates p < 0.05, ** indicates p < 0.01. n.s. = not significant. b ) Representative graphs of prostate cancer EVs distribution from NTA software. c )Immunoblotting analysis of EVs from <t>PC-3,</t> LNCaP and DU 145 cells and cell lysates. Detection of EVs associated positive markers, syntenin, CD63, and negative marker calnexin. SEM images of d ) PC-3 EVs, e ) LNCaP EVs and f) DU 145 EVs with a range of 90 nm to 130 nm (magnification 62000x).
    Androgen Independent Prostate Carcinoma Pc 3 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/androgen independent prostate carcinoma pc 3 cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    androgen independent prostate carcinoma pc 3 cell line - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier
    androgen independent 248 prostate carcinoma pc 3 cell line  (ATCC)
    99
    ATCC androgen independent 248 prostate carcinoma pc 3 cell line
    Characterisation of prostate cancer-derived extracellular vesicles. EVs post differential ultracentrifugation were characterised using nanoparticle tracking analysis (NTA), immunoblotting analysis, and scanning electron microscopy (SEM). a ). Particle concentration and size of which three replicates of each sample were analysed by NTA independently. Data analysed by one-way ANOVA test and presented as mean bars (n = 3) ± SEM, the significant p-value is reported; * indicates p < 0.05, ** indicates p < 0.01. n.s. = not significant. b ) Representative graphs of prostate cancer EVs distribution from NTA software. c )Immunoblotting analysis of EVs from <t>PC-3,</t> LNCaP and DU 145 cells and cell lysates. Detection of EVs associated positive markers, syntenin, CD63, and negative marker calnexin. SEM images of d ) PC-3 EVs, e ) LNCaP EVs and f) DU 145 EVs with a range of 90 nm to 130 nm (magnification 62000x).
    Androgen Independent 248 Prostate Carcinoma Pc 3 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/androgen independent 248 prostate carcinoma pc 3 cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    androgen independent 248 prostate carcinoma pc 3 cell line - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Characterisation of prostate cancer-derived extracellular vesicles. EVs post differential ultracentrifugation were characterised using nanoparticle tracking analysis (NTA), immunoblotting analysis, and scanning electron microscopy (SEM). a ). Particle concentration and size of which three replicates of each sample were analysed by NTA independently. Data analysed by one-way ANOVA test and presented as mean bars (n = 3) ± SEM, the significant p-value is reported; * indicates p < 0.05, ** indicates p < 0.01. n.s. = not significant. b ) Representative graphs of prostate cancer EVs distribution from NTA software. c )Immunoblotting analysis of EVs from PC-3, LNCaP and DU 145 cells and cell lysates. Detection of EVs associated positive markers, syntenin, CD63, and negative marker calnexin. SEM images of d ) PC-3 EVs, e ) LNCaP EVs and f) DU 145 EVs with a range of 90 nm to 130 nm (magnification 62000x).

    Journal: Scientific Reports

    Article Title: Immune profiling identifies the contribution of extracellular vesicles to immune modulation and progression in prostate cancer

    doi: 10.1038/s41598-025-31838-w

    Figure Lengend Snippet: Characterisation of prostate cancer-derived extracellular vesicles. EVs post differential ultracentrifugation were characterised using nanoparticle tracking analysis (NTA), immunoblotting analysis, and scanning electron microscopy (SEM). a ). Particle concentration and size of which three replicates of each sample were analysed by NTA independently. Data analysed by one-way ANOVA test and presented as mean bars (n = 3) ± SEM, the significant p-value is reported; * indicates p < 0.05, ** indicates p < 0.01. n.s. = not significant. b ) Representative graphs of prostate cancer EVs distribution from NTA software. c )Immunoblotting analysis of EVs from PC-3, LNCaP and DU 145 cells and cell lysates. Detection of EVs associated positive markers, syntenin, CD63, and negative marker calnexin. SEM images of d ) PC-3 EVs, e ) LNCaP EVs and f) DU 145 EVs with a range of 90 nm to 130 nm (magnification 62000x).

    Article Snippet: The androgen-dependent LNCaP metastatic prostate carcinoma cell line (CRL-1740), androgen-independent prostate carcinoma PC-3 cell line (CRL-1435) and androgen-independent prostate carcinoma DU 145 cell line (HTB-81) were purchased from the American Type Culture Collection (ATCC).

    Techniques: Derivative Assay, Western Blot, Electron Microscopy, Concentration Assay, Software, Marker

    Effect of PC-3 and LNCaP EVs on monocyte populations. PBMCs were treated with PC-3 EVs, LNCaP EVs, DU 145 EVs and t-NEPC LNCaP EVs for 24 h. a ) Comparison of % CD14 + CD16 + rare monocytes from 10 healthy volunteers treated with EVs derived from PC-3, LNCaP and DU 145. b ) Comparison of % CD14 + CD16 + rare monocytes treated with EVs derived from PC-3, LNCaP and DU 145 in respect to the untreated samples (CTRL). c ) Comparison of % CD14 + CD16 + rare monocytes treated with EVs derived from PC-3 compared to t-NEPC LNCaP treated cells. Data analysed by one-way ANOVA and presented as mean bars (n = 10) ± SEM, the significant p -value is reported; **** p < 0.0001; *** indicates p < 0.001; n.s. = not significant.

    Journal: Scientific Reports

    Article Title: Immune profiling identifies the contribution of extracellular vesicles to immune modulation and progression in prostate cancer

    doi: 10.1038/s41598-025-31838-w

    Figure Lengend Snippet: Effect of PC-3 and LNCaP EVs on monocyte populations. PBMCs were treated with PC-3 EVs, LNCaP EVs, DU 145 EVs and t-NEPC LNCaP EVs for 24 h. a ) Comparison of % CD14 + CD16 + rare monocytes from 10 healthy volunteers treated with EVs derived from PC-3, LNCaP and DU 145. b ) Comparison of % CD14 + CD16 + rare monocytes treated with EVs derived from PC-3, LNCaP and DU 145 in respect to the untreated samples (CTRL). c ) Comparison of % CD14 + CD16 + rare monocytes treated with EVs derived from PC-3 compared to t-NEPC LNCaP treated cells. Data analysed by one-way ANOVA and presented as mean bars (n = 10) ± SEM, the significant p -value is reported; **** p < 0.0001; *** indicates p < 0.001; n.s. = not significant.

    Article Snippet: The androgen-dependent LNCaP metastatic prostate carcinoma cell line (CRL-1740), androgen-independent prostate carcinoma PC-3 cell line (CRL-1435) and androgen-independent prostate carcinoma DU 145 cell line (HTB-81) were purchased from the American Type Culture Collection (ATCC).

    Techniques: Comparison, Derivative Assay

    PC-3-EVs effects on innate lymphoid and NK cells compared to LNCaP-EVs. Effect of prostate cancer EVs on innate immune cells. a ) The percentage of CD4 + HLA-DR + after treatment with EVs derived from PC-3 and DU 145 compared to LNCaP treatment. b ) The percentage of CD8 + HLA-DR + treated with EVs derived from PC-3 and DU 145 in comparison to LNCaP treatment. c ) Comparison of the ratio of CD4 + HLA-DR + regarding the CD4 + . d ) Comparison of ratio of CD8 + HLA-DR + in regard to the CD8 + . Data analysed by one-way ANOVA and presented as mean bars (n = 10) ± SEM, the significant p -value is reported; * indicates p < 0.05; n.s. = not significant.

    Journal: Scientific Reports

    Article Title: Immune profiling identifies the contribution of extracellular vesicles to immune modulation and progression in prostate cancer

    doi: 10.1038/s41598-025-31838-w

    Figure Lengend Snippet: PC-3-EVs effects on innate lymphoid and NK cells compared to LNCaP-EVs. Effect of prostate cancer EVs on innate immune cells. a ) The percentage of CD4 + HLA-DR + after treatment with EVs derived from PC-3 and DU 145 compared to LNCaP treatment. b ) The percentage of CD8 + HLA-DR + treated with EVs derived from PC-3 and DU 145 in comparison to LNCaP treatment. c ) Comparison of the ratio of CD4 + HLA-DR + regarding the CD4 + . d ) Comparison of ratio of CD8 + HLA-DR + in regard to the CD8 + . Data analysed by one-way ANOVA and presented as mean bars (n = 10) ± SEM, the significant p -value is reported; * indicates p < 0.05; n.s. = not significant.

    Article Snippet: The androgen-dependent LNCaP metastatic prostate carcinoma cell line (CRL-1740), androgen-independent prostate carcinoma PC-3 cell line (CRL-1435) and androgen-independent prostate carcinoma DU 145 cell line (HTB-81) were purchased from the American Type Culture Collection (ATCC).

    Techniques: Derivative Assay, Comparison

    Release of cytokines by immune cells after treatment with prostate cancer EVs. Seven pro- and anti-inflammatory cytokines were evaluated from the conditioned medium of PBMCs from 10 healthy donors and samples treated with PC-3-EVs, LNCaP-EVs and DU 145 EVs for 24h. a ) Level of IL-6 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. b ) Level of MIP-1α between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. c ) Level of IL-7 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. d ) Level of IFN-α2 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. e ) Level of IL-10 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. f ) Level of MCP-1 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. g ) Level of G-CSF between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. Data analysed by one-way ANOVA and presented as mean bars (n = 10) ± SEM, the significant p -value is reported; **** indicates p < 0.0001; ***indicates p < 0.001; ** indicates p < 0.01; *indicates p < 0.05.

    Journal: Scientific Reports

    Article Title: Immune profiling identifies the contribution of extracellular vesicles to immune modulation and progression in prostate cancer

    doi: 10.1038/s41598-025-31838-w

    Figure Lengend Snippet: Release of cytokines by immune cells after treatment with prostate cancer EVs. Seven pro- and anti-inflammatory cytokines were evaluated from the conditioned medium of PBMCs from 10 healthy donors and samples treated with PC-3-EVs, LNCaP-EVs and DU 145 EVs for 24h. a ) Level of IL-6 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. b ) Level of MIP-1α between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. c ) Level of IL-7 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. d ) Level of IFN-α2 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. e ) Level of IL-10 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. f ) Level of MCP-1 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. g ) Level of G-CSF between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. Data analysed by one-way ANOVA and presented as mean bars (n = 10) ± SEM, the significant p -value is reported; **** indicates p < 0.0001; ***indicates p < 0.001; ** indicates p < 0.01; *indicates p < 0.05.

    Article Snippet: The androgen-dependent LNCaP metastatic prostate carcinoma cell line (CRL-1740), androgen-independent prostate carcinoma PC-3 cell line (CRL-1435) and androgen-independent prostate carcinoma DU 145 cell line (HTB-81) were purchased from the American Type Culture Collection (ATCC).

    Techniques:

    Characterisation of prostate cancer-derived extracellular vesicles. EVs post differential ultracentrifugation were characterised using nanoparticle tracking analysis (NTA), immunoblotting analysis, and scanning electron microscopy (SEM). a ). Particle concentration and size of which three replicates of each sample were analysed by NTA independently. Data analysed by one-way ANOVA test and presented as mean bars (n = 3) ± SEM, the significant p-value is reported; * indicates p < 0.05, ** indicates p < 0.01. n.s. = not significant. b ) Representative graphs of prostate cancer EVs distribution from NTA software. c )Immunoblotting analysis of EVs from PC-3, LNCaP and DU 145 cells and cell lysates. Detection of EVs associated positive markers, syntenin, CD63, and negative marker calnexin. SEM images of d ) PC-3 EVs, e ) LNCaP EVs and f) DU 145 EVs with a range of 90 nm to 130 nm (magnification 62000x).

    Journal: Scientific Reports

    Article Title: Immune profiling identifies the contribution of extracellular vesicles to immune modulation and progression in prostate cancer

    doi: 10.1038/s41598-025-31838-w

    Figure Lengend Snippet: Characterisation of prostate cancer-derived extracellular vesicles. EVs post differential ultracentrifugation were characterised using nanoparticle tracking analysis (NTA), immunoblotting analysis, and scanning electron microscopy (SEM). a ). Particle concentration and size of which three replicates of each sample were analysed by NTA independently. Data analysed by one-way ANOVA test and presented as mean bars (n = 3) ± SEM, the significant p-value is reported; * indicates p < 0.05, ** indicates p < 0.01. n.s. = not significant. b ) Representative graphs of prostate cancer EVs distribution from NTA software. c )Immunoblotting analysis of EVs from PC-3, LNCaP and DU 145 cells and cell lysates. Detection of EVs associated positive markers, syntenin, CD63, and negative marker calnexin. SEM images of d ) PC-3 EVs, e ) LNCaP EVs and f) DU 145 EVs with a range of 90 nm to 130 nm (magnification 62000x).

    Article Snippet: The androgen-dependent LNCaP metastatic prostate carcinoma cell line (CRL-1740), androgen-independent prostate carcinoma PC-3 cell line (CRL-1435) and androgen-independent prostate carcinoma DU 145 cell line (HTB-81) were purchased from the American Type Culture Collection (ATCC).

    Techniques: Derivative Assay, Western Blot, Electron Microscopy, Concentration Assay, Software, Marker

    Effect of PC-3 and LNCaP EVs on monocyte populations. PBMCs were treated with PC-3 EVs, LNCaP EVs, DU 145 EVs and t-NEPC LNCaP EVs for 24 h. a ) Comparison of % CD14 + CD16 + rare monocytes from 10 healthy volunteers treated with EVs derived from PC-3, LNCaP and DU 145. b ) Comparison of % CD14 + CD16 + rare monocytes treated with EVs derived from PC-3, LNCaP and DU 145 in respect to the untreated samples (CTRL). c ) Comparison of % CD14 + CD16 + rare monocytes treated with EVs derived from PC-3 compared to t-NEPC LNCaP treated cells. Data analysed by one-way ANOVA and presented as mean bars (n = 10) ± SEM, the significant p -value is reported; **** p < 0.0001; *** indicates p < 0.001; n.s. = not significant.

    Journal: Scientific Reports

    Article Title: Immune profiling identifies the contribution of extracellular vesicles to immune modulation and progression in prostate cancer

    doi: 10.1038/s41598-025-31838-w

    Figure Lengend Snippet: Effect of PC-3 and LNCaP EVs on monocyte populations. PBMCs were treated with PC-3 EVs, LNCaP EVs, DU 145 EVs and t-NEPC LNCaP EVs for 24 h. a ) Comparison of % CD14 + CD16 + rare monocytes from 10 healthy volunteers treated with EVs derived from PC-3, LNCaP and DU 145. b ) Comparison of % CD14 + CD16 + rare monocytes treated with EVs derived from PC-3, LNCaP and DU 145 in respect to the untreated samples (CTRL). c ) Comparison of % CD14 + CD16 + rare monocytes treated with EVs derived from PC-3 compared to t-NEPC LNCaP treated cells. Data analysed by one-way ANOVA and presented as mean bars (n = 10) ± SEM, the significant p -value is reported; **** p < 0.0001; *** indicates p < 0.001; n.s. = not significant.

    Article Snippet: The androgen-dependent LNCaP metastatic prostate carcinoma cell line (CRL-1740), androgen-independent prostate carcinoma PC-3 cell line (CRL-1435) and androgen-independent prostate carcinoma DU 145 cell line (HTB-81) were purchased from the American Type Culture Collection (ATCC).

    Techniques: Comparison, Derivative Assay

    PC-3-EVs effects on innate lymphoid and NK cells compared to LNCaP-EVs. Effect of prostate cancer EVs on innate immune cells. a ) The percentage of CD4 + HLA-DR + after treatment with EVs derived from PC-3 and DU 145 compared to LNCaP treatment. b ) The percentage of CD8 + HLA-DR + treated with EVs derived from PC-3 and DU 145 in comparison to LNCaP treatment. c ) Comparison of the ratio of CD4 + HLA-DR + regarding the CD4 + . d ) Comparison of ratio of CD8 + HLA-DR + in regard to the CD8 + . Data analysed by one-way ANOVA and presented as mean bars (n = 10) ± SEM, the significant p -value is reported; * indicates p < 0.05; n.s. = not significant.

    Journal: Scientific Reports

    Article Title: Immune profiling identifies the contribution of extracellular vesicles to immune modulation and progression in prostate cancer

    doi: 10.1038/s41598-025-31838-w

    Figure Lengend Snippet: PC-3-EVs effects on innate lymphoid and NK cells compared to LNCaP-EVs. Effect of prostate cancer EVs on innate immune cells. a ) The percentage of CD4 + HLA-DR + after treatment with EVs derived from PC-3 and DU 145 compared to LNCaP treatment. b ) The percentage of CD8 + HLA-DR + treated with EVs derived from PC-3 and DU 145 in comparison to LNCaP treatment. c ) Comparison of the ratio of CD4 + HLA-DR + regarding the CD4 + . d ) Comparison of ratio of CD8 + HLA-DR + in regard to the CD8 + . Data analysed by one-way ANOVA and presented as mean bars (n = 10) ± SEM, the significant p -value is reported; * indicates p < 0.05; n.s. = not significant.

    Article Snippet: The androgen-dependent LNCaP metastatic prostate carcinoma cell line (CRL-1740), androgen-independent prostate carcinoma PC-3 cell line (CRL-1435) and androgen-independent prostate carcinoma DU 145 cell line (HTB-81) were purchased from the American Type Culture Collection (ATCC).

    Techniques: Derivative Assay, Comparison

    T-NEPC LNCaP EVs effects on innate lymphoid and NK cells. Effect of t-NEPC LNCaP EVs on innate immune cells. a ) The percentage of CD4 + HLA-DR + after treatment with EVs derived from PC-3 compared to t-NEPC LNCaP treatment. b ) The percentage of CD8 + HLA-DR + treated with EVs derived from PC-3 compared to t-NEPC LNCaP treatment. c ) Comparison of the ratio of CD4 + HLA-DR + regarding the CD4 + . d ) Comparison of ratio of CD8 + HLA-DR + in regard to the CD8 + . Data analysed by parametric t-test and presented as mean bars (n = 10) ± SEM, the significant p -value is reported; * indicates p < 0.05; n.s. = not significant.

    Journal: Scientific Reports

    Article Title: Immune profiling identifies the contribution of extracellular vesicles to immune modulation and progression in prostate cancer

    doi: 10.1038/s41598-025-31838-w

    Figure Lengend Snippet: T-NEPC LNCaP EVs effects on innate lymphoid and NK cells. Effect of t-NEPC LNCaP EVs on innate immune cells. a ) The percentage of CD4 + HLA-DR + after treatment with EVs derived from PC-3 compared to t-NEPC LNCaP treatment. b ) The percentage of CD8 + HLA-DR + treated with EVs derived from PC-3 compared to t-NEPC LNCaP treatment. c ) Comparison of the ratio of CD4 + HLA-DR + regarding the CD4 + . d ) Comparison of ratio of CD8 + HLA-DR + in regard to the CD8 + . Data analysed by parametric t-test and presented as mean bars (n = 10) ± SEM, the significant p -value is reported; * indicates p < 0.05; n.s. = not significant.

    Article Snippet: The androgen-dependent LNCaP metastatic prostate carcinoma cell line (CRL-1740), androgen-independent prostate carcinoma PC-3 cell line (CRL-1435) and androgen-independent prostate carcinoma DU 145 cell line (HTB-81) were purchased from the American Type Culture Collection (ATCC).

    Techniques: Derivative Assay, Comparison

    Release of cytokines by immune cells after treatment with prostate cancer EVs. Seven pro- and anti-inflammatory cytokines were evaluated from the conditioned medium of PBMCs from 10 healthy donors and samples treated with PC-3-EVs, LNCaP-EVs and DU 145 EVs for 24h. a ) Level of IL-6 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. b ) Level of MIP-1α between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. c ) Level of IL-7 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. d ) Level of IFN-α2 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. e ) Level of IL-10 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. f ) Level of MCP-1 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. g ) Level of G-CSF between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. Data analysed by one-way ANOVA and presented as mean bars (n = 10) ± SEM, the significant p -value is reported; **** indicates p < 0.0001; ***indicates p < 0.001; ** indicates p < 0.01; *indicates p < 0.05.

    Journal: Scientific Reports

    Article Title: Immune profiling identifies the contribution of extracellular vesicles to immune modulation and progression in prostate cancer

    doi: 10.1038/s41598-025-31838-w

    Figure Lengend Snippet: Release of cytokines by immune cells after treatment with prostate cancer EVs. Seven pro- and anti-inflammatory cytokines were evaluated from the conditioned medium of PBMCs from 10 healthy donors and samples treated with PC-3-EVs, LNCaP-EVs and DU 145 EVs for 24h. a ) Level of IL-6 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. b ) Level of MIP-1α between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. c ) Level of IL-7 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. d ) Level of IFN-α2 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. e ) Level of IL-10 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. f ) Level of MCP-1 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. g ) Level of G-CSF between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. Data analysed by one-way ANOVA and presented as mean bars (n = 10) ± SEM, the significant p -value is reported; **** indicates p < 0.0001; ***indicates p < 0.001; ** indicates p < 0.01; *indicates p < 0.05.

    Article Snippet: The androgen-dependent LNCaP metastatic prostate carcinoma cell line (CRL-1740), androgen-independent prostate carcinoma PC-3 cell line (CRL-1435) and androgen-independent prostate carcinoma DU 145 cell line (HTB-81) were purchased from the American Type Culture Collection (ATCC).

    Techniques: